Literature DB >> 14733725

The dual role of LBP and CD14 in response to Gram-negative bacteria or Gram-negative compounds.

Didier Heumann1, Roger Lauener, Bernard Ryffel.   

Abstract

Innate immunity initiates protection of the host organism against invasion of micro-organisms by specific recognition mechanisms. This article reviews the dual role of LBP/CD14 in innate immunity, focusing mostly on experiments performed in mice by the authors. LPS induces uncontrolled pro-inflammatory response that kills the host and is LBP- and CD14-dependent, as neutralization of LBP and CD14 prevents lethal shock. However, surprisingly, the synthetic Pam3CysSerLys4 bacterial lipoprotein from Escherichia coli (BLP), which is well tolerated in mice, kills the mice upon LBP or CD14 blockade. Furthermore, after blockade of LBP and CD14, the mice succumb to a challenge with virulent Klebsiella pneumoniae or Salmonella typhimurium. Therefore, host responses to Gram-negative bacteria are not identical to that of LPS or BLP. When the host is in the presence of virulent Gram-negative bacteria, the invading pathogens must be held in check by the innate immune system until a specific immune response is mounted. Under these conditions, LBP, CD14, and likely Toll-like receptors (TLRs) are a prerequisite to trigger a pro-inflammatory response of macrophages, which is crucial for keeping an infection under control. These studies indicate that we are very far from understanding how the innate system works and more work needs to be done concerning LBP, CD14 or TLRs. Therefore, caution should be the rule about the use of therapeutic approaches to block the pro-inflammatory response in Gram-negative infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14733725     DOI: 10.1179/096805103225003312

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  7 in total

1.  Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis.

Authors:  Fabio Alessandro Facchini; Davide Di Fusco; Simona Barresi; Andrea Luraghi; Alberto Minotti; Francesca Granucci; Giovanni Monteleone; Francesco Peri; Ivan Monteleone
Journal:  Eur J Clin Pharmacol       Date:  2020-01-25       Impact factor: 2.953

2.  Human biomarker discovery and predictive models for disease progression for idiopathic pneumonia syndrome following allogeneic stem cell transplantation.

Authors:  Daniela M Schlatzer; Jean-Eudes Dazard; Rob M Ewing; Serguei Ilchenko; Sara E Tomcheko; Saada Eid; Vincent Ho; Greg Yanik; Mark R Chance; Kenneth R Cooke
Journal:  Mol Cell Proteomics       Date:  2012-02-15       Impact factor: 5.911

3.  Suppressed Th17 levels correlate with elevated PIAS3, SHP2, and SOCS3 expression in CD4 T cells during acute simian immunodeficiency virus infection.

Authors:  Sandra L Bixler; Netanya G Sandler; Daniel C Douek; Joseph J Mattapallil
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

4.  Directed evolution of an LBP/CD14 inhibitory peptide and its anti-endotoxin activity.

Authors:  Li Fang; Zhi Xu; Guan-song Wang; Fu-yun Ji; Chun-xia Mei; Juan Liu; Guo-ming Wu
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

5.  Lipopolysaccharide-binding protein as a risk factor for development of infectious and inflammatory postsurgical complications in colorectal cancer paients.

Authors:  Yermek Turgunov; Alina Ogizbayeva; Lyudmila Akhmaltdinova; Kayrat Shakeyev
Journal:  Contemp Oncol (Pozn)       Date:  2021-10-14

6.  Identification and Characterization of Zebrafish Tlr4 Coreceptor Md-2.

Authors:  Andrea N Loes; Melissa N Hinman; Dylan R Farnsworth; Adam C Miller; Karen Guillemin; Michael J Harms
Journal:  J Immunol       Date:  2021-01-20       Impact factor: 5.422

7.  Periodontal CD14 mRNA expression is downregulated in patients with chronic periodontitis and type 2 diabetes.

Authors:  Dustin C Hedgpeth; Xiaoming Zhang; Junfei Jin; Renata S Leite; Joe W Krayer; Yan Huang
Journal:  BMC Oral Health       Date:  2015-11-18       Impact factor: 2.757

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.